Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.

Abstract: Disclosed are methods and systems correcting bulk-motion artifacts in phase-based functional OCT images. The disclosed methods and systems are based on the use of the standard deviation of the phase shift signal present in phase-based OCT imaging. When applied with functional OCT techniques such as OCT angiography, Doppler OCT, and OCT elastography, the disclosed methods provide improved image quality and decreased computational cost compared to other methods of bulk motion compensation.

Abstract: Disclosed herein are methods and systems for optical coherence tomography (OCT) angiography (OCTA). An interleaved scanning pattern is described herein for both raster and bidirectional scanning methods. The interleaved scanning pattern provides B-scans with different scanning intervals. OCTA images based on the B-scans may be combined to obtain a high dynamic range (HDR) OCTA image. Other embodiments may be described and claimed.

Abstract: The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are immunogenic constructs including: a nanoparticle; a cationic polymer electrostatically bound to an exterior surface of the nanoparticle and a stabilizer bound to the cationic polymer or the exterior surface of the nanoparticle; and an antigen or antigen producing agent. Optionally, the constructs may include adjuvant and/or one or more functional oligonucleotide(s) (e.g., siRNA or pDNA). Also disclosed are methods of using the provided immunogenic constructs for co-delivering an adjuvant, antigen, and optionally siRNA to a cell, inducing immune response in a subject, and treating or preventing an infectious disease in a subject.

Abstract: Disclosed are methods and systems for signal attenuation-compensated projection-resolved (sacPR) optical coherence tomography angiography (OCTA). The sacPR OCTA may be free of segmentation and vascular contrast enhancement. In some embodiments, projection artifacts may be suppressed with signal compensation including flow and large vessel shadow compensation for projection removal and wavelet-based compensation for noise suppression.

Abstract: Disclosed is a handheld laser probe for laser thermal conjunctivoplasty, the handheld laser comprising: a forceps; and a line focused laser light source coupled to the forceps, wherein the forceps are configured to grasp a conjunctival fold and hold the fold in a light beam of the line focused laser, and wherein the line focused laser beam is configured to uniformly heat the conjunctival fold held in the forceps. Disclosed are systems for laser thermal conjunctivoplasty including the handheld laser. Disclosed are methods of conjunctivoplasty using the handheld laser probe.

Abstract: Methods and systems for identifying CNV membranes and vasculature in images obtained using noninvasive imaging techniques are described. An example method includes generating, by a first model based on at least one image of a retina of a subject, a membrane mask indicating a location of a CNV membrane in the retina. The method further includes generating, by a second model based on the membrane mask and the at least one image, a vasculature mask of the retina of the subject, the vasculature mask indicating CNV vascularization in the retina.

Abstract: Provided herein are novel azopodophyllotoxin analog compounds, pharmaceutical compositions comprising them, and their use as inhibitors of Y box protein 1 (YB1 or YBX1) in treatments for conditions including gynecological, breast, bladder, kidney, head and neck, neuronal, and prostate cancers, lymphomas, and leukemias. Methods of their use in sensitizing resistant cancers to treatment with anticancer agents and radiation are also provided.

Abstract: Embodiments include a delivery device for an auxetic device. The delivery device is comprised of an outer constraining device and a longitudinal controlling device disposed concentrically within the outer constraining device and offset to form a chamber for receiving the auxetic device. A mechanism coupled to the outer constraining device and the longitudinal controlling device allows the chamber size to adjust longitudinally as the auxetic device is deployed. Other embodiments may be described and/or claimed.

Abstract: Disclosed is a handheld laser probe for laser thermal conjunctivoplasty, the handheld laser comprising: a forceps; and a line focused laser light source coupled to the forceps, wherein the forceps are configured to grasp a conjunctival fold and hold the fold in a light beam of the line focused laser, and wherein the line focused laser beam is configured to uniformly heat the conjunctival fold held in the forceps. Disclosed are systems for laser thermal conjunctivoplasty including the handheld laser. Disclosed are methods of conjunctivoplasty using the handheld laser probe.

Abstract: Disclosed are adeno-associated viral vectors and plasmids encoding the same. Also disclosed are methods of using adeno-associated viral vectors to deliver a protein of interest to the subject. The disclosed vectors have phenotypes including but not limited to increased retention in the blood of a subject, avoidance of the liver, and transduction of the brain and other tissues.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: Disclosed herein is a method for detecting retinal pathologies in three dimensions using structural and angiographic OCT. The method in accordance with the present disclosure may operate by detecting deviations in reflectance and perfusion from a depth-normalized standard retina created by merging and averaging scans from healthy subjects. In one example, the deviations from the standard retina highlight key pathologic features, while depth-normalization obviates the need to segment retinal layers. Additionally, a composite pathology index is disclosed herein that measures average deviation from the standard retina. The present method is amenable to automation and may be implemented in an integrated system and/or provided in the form of software encoded on a computer-readable medium.

Abstract: A compact material testing system is configured to expose multiple samples housed within separate sample chambers to simulated fluid, thermal, and mechanical loading conditions. The system includes multiple independent load actuators positioned to extend actuator rods into corresponding sample chambers to apply mechanical loading to the test sample within. A fluid control system is included to bathe each test sample in a fluid medium and replenish the fluid medium within its sample chamber as needed. Each sample chamber includes a gas inlet and gas outlet to provide non-turbulent circulation and control of atmospheric composition above the fluid medium inside the chamber. A logic programmable controller is provided for input of test parameters and automated simultaneous control of mechanical loading, fluid flow, and temperature in the sample chambers.

Abstract: Provided is an ex vivo system allowing for assessment of tumor and other cell responses to pluralities of agents or agent combinations using a microdose delivery microdevice implanted into an ex vivo tissue sample. The microdevice permits localized intra-tissue sample agent delivery and provides the ability to predict the drug efficacy within days after application. Systems for maintaining tissue samples ex vivo over hours to weeks are provided, which can be used to house tissue samples during exposure of the tissue to microdoses of agents applied using the delivery microdevices. Also provided are biomarkers (galectin and/or neuropilin) useful in evaluating the efficacy of agents.

Abstract: A method using a specially configured computer display support structure reduces occurrences of medical errors by facilitating real-time, synchronous review of medical data by rounding professionals during patient rounds. The support structure includes an upright column assembly that has a column assembly base and six sides. Mounting brackets fixed to non-contiguous sides of the column assembly receive back plates of a system device mounting assembly, each of which includes a pivot arm that receives a system device arm. The system device arm is pivotable at opposing ends and terminates in a coupling member at its distal end. The coupling member is connected to a video display that has an angularly positionable display screen. In some embodiments, a keyboard tray, on which a keyboard and computer mouse rest, is connected to the coupling member.

Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.

Abstract: Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.